DENVER--(BUSINESS WIRE)--Sept. 5, 2006--Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced that an abstract describing the effects of ambrisentan in patients with pulmonary arterial hypertension (PAH) has been selected for presentation at the World Congress of Cardiology 2006, a joint meeting of the European Society of Cardiology and the World Heart Federation, to be held September 2-6, 2006 in Barcelona, Spain.
